Drug Trial Radar · NCT04516096
A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)
Last checked: Nov 19, 2026Latest source record: Apr 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Nov 22, 2020
Primary completion
Dec 30, 2022
Study completion Jan 31, 2023
Sponsor
- Lead sponsor
- Amylyx Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 18, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The protocol is intended to provide extended treatment with AMX0035 to patients who previously participated in an Amylyx sponsored study of AMX0035 for ALS.
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
AMX0035Drug
Tauroursodeoxycholic Acid and Sodium Phenylbutyrate orally given twice a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment emergent Adverse EventsTime frame: Through study completion an average of 1 year
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Forbes Norris MDA/ALS Research Center - California Pacific Medical Center
San Francisco, California
Massachusetts General Hospital
Boston, Massachusetts
University of Massachusetts Memorial Medical Center
Worcester, Massachusetts
University of Michigan Medical Center
Ann Arbor, Michigan
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.